Skip to main content

ORTHOFIX International N V Value Stock - Dividend - Research Selection

Orthofix international n v

ISIN: US68752M1080 , WKN: A2NB0X

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Orthofix International N.V., a medical device company, provides musculoskeletal healing products and value-added services worldwide. It operates through four segments: BioStim, Extremity Fixation, Spine Fixation, and Biologics. The BioStim segment manufactures, distributes, and provides support services for bone growth stimulator devices that enhance bone fusion and are indicated as treatment to enhance fusion success rates in cervical and lumbar spine, as well as a therapeutic treatment for non-spine fractures. The Extremity Fixation segment designs, develops, and markets orthopedic products used in fracture repair, deformity correction, and bone reconstruction procedures. The Spine Fixation segment designs, develops, and markets a portfolio of implant products used in surgical procedures of the spine. The Biologics segment provides a portfolio of regenerative products and tissue forms that allow physicians to treat a range of spinal and orthopedic conditions. The company markets and distributes its products through direct sales representatives; independent distributors; and employed and independent sales representatives to physicians, hospitals, ambulatory surgery centers, integrated health delivery systems, and other purchasing organizations. Orthofix International N.V. was founded in 1987 and is headquartered in Lewisville, Texas.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Orthofix Medical's (NASDAQ:OFIX) investors will be pleased with their decent 76% return over the last year

2024-12-01
Passive investing in index funds can generate returns that roughly match the overall market. But investors can boost...

Orthofix to Participate in Upcoming Investor Conferences

2024-11-12
LEWISVILLE, Texas, November 12, 2024--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that Massimo Calafiore, President and Chief Executive Officer, and Julie Andrews, Chief Financial Officer, will participate in the following investor conferences:

Orthofix Medical Inc. (OFIX) Q3 2024 Earnings Call Transcript

2024-11-10
Orthofix Medical Inc. (NASDAQ:OFIX) Q3 2024 Results Conference Call November 7, 2024 8:30 AM ETCompany ParticipantsJulie Dewey - Chief IR and Communications...

Orthofix Reports Q3 Sales Growth and New Financial Targets

2024-11-08
An announcement from Orthofix ( (OFIX) ) is now available. Orthofix Medical Inc. reported a 7% increase in third-quarter 2024 net sales, reaching $196.6 million, driven by strong performance in U.S. markets, including 18% growth in Spine Fixation and 15% in Orthopedics. Despite a net loss of $27.4 million, the company achieved a significant EBITDA margin expansion and positive free cash flow. Orthofix also introduced new three-year financial targets and announced a $275 million credit facility t

Orthofix Medical Inc (OFIX) Q3 2024 Earnings Call Highlights: Strong Growth in US Spine ...

2024-11-08
Orthofix Medical Inc (OFIX) reports a robust third quarter with significant revenue growth across key segments, despite challenges in international markets.

OFIX INVESTORS: OrthoFix Medical Inc. Stockholders Should Contact Robbins LLP About Joining the Pending OFIX Class Action

2024-11-07
SAN DIEGO, Nov. 7, 2024 /PRNewswire/ -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of former SeaSpine Holdings Corporation shareholders that purchased or...

Orthofix (OFIX) Q3 Earnings Surpass Estimates

2024-11-07
Orthofix (OFIX) delivered earnings and revenue surprises of 150% and 0%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Orthofix: Q3 Earnings Snapshot

2024-11-07
LEWISVILLE, Texas (AP) — Orthofix Medical Inc. OFIX) on Thursday reported a loss of $27.4 million in its third quarter. On a per-share basis, the Lewisville, Texas-based company said it had a loss of 71 cents.

Orthofix Announces New Term Loan

2024-11-07
LEWISVILLE, Texas, November 07, 2024--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced the entry into a new credit agreement providing the Company with up to $275 million in a senior-secured term loan with a 48-month interest only period. The term loan is agented by Oxford Finance LLC ("Oxford") and provides non-dilutive capital and financial flexibility to support Orthofix’s continued focus on profitable growth. The proceeds from the initial fund

Orthofix Reports Third Quarter 2024 Results, Reiterates Full-Year 2024 Financial Guidance, and Introduces New Three-Year Financial Targets

2024-11-07
LEWISVILLE, Texas, November 07, 2024--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the third quarter ended September 30, 2024, reiterated its full-year 2024 financial guidance, and introduced new three-year financial targets.